AmebaGone Inc. will solve one of the 21st century’s most compelling problems -- that of growing antibiotic resistance alongside a dwindling supply of effective antimicrobial products. Antibiotic resistance is a worldwide problem that manifests itself in agriculture and in human and animal health. And while the threat of infectious disease is intensifying, the discovery of new antibiotics has slowed dramatically. Pharmaceutical companies have largely abandoned the discovery of new antibiotics, despite the liklihood of an impending health crisis. AmebaGone 's team is stepping boldly in to explore new antimicrobial strategies, integrating its proprietary technology reliant on the use of benign, free-living phagocytes to combat bacterial pathogens in crops, animals and humans.
Moreover, AmebaGone's propriatary technology can combat biofilm-encased pathogens, which also cause costly and time-consuming problems such as microbial influenced corrosion and fouling for industry.
Amebagone Inc. Receives Certification as a Qualified New Business Venture from the Wisconsin Economic Development Corporation
Amebagone Inc. awarded National Science Foundation SBIR Phase II funding to develop natural biocides